(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of -51.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 22.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Arbutus Biopharma's revenue in 2026 is $191,445,000.On average, 4 Wall Street analysts forecast ABUS's revenue for 2026 to be $18,355,599,089, with the lowest ABUS revenue forecast at $193,586,956, and the highest ABUS revenue forecast at $37,583,524,705.
In 2027, ABUS is forecast to generate $544,018,853 in revenue, with the lowest revenue forecast at $522,684,781 and the highest revenue forecast at $560,019,408.